Abstracts tagged "Biologics"

Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…
Abstract Number: 564 • 2018 ACR/ARHP Annual Meeting
Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)
Katie Tuckwell¹, Cem Gabay², Thierry Sornasse¹, Ruediger Laubender³, Jianmei Wang⁴ and Michael Townsend¹, ¹Genentech, Inc., South San Francisco, CA, ²University Hospitals of Geneva, Geneva, Switzerland, ³Roche Diagnostics, Penzberg, Germany, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: The biomarkers CXCL13 and sICAM1 have been associated with outcomes in patients with RA treated with TCZ. This study evaluated the association of CXCL13…
Abstract Number: 1489 • 2018 ACR/ARHP Annual Meeting
“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment
Takayoshi Owada¹, Kazuhiro Kurasawa¹, Yuta Takamura¹, Tomoyuki Miyao¹, Ayae Tanaka¹, Ryutaro Yamazaki², Satoko Arai¹, Reika Maezawa¹ and Masafumi Arima³, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan, ³Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan
Background/Purpose: Relative change of serum RF titer has been reported to correlate with those of RA disease activity. However, it is debatable whether serum RF…
Abstract Number: 2453 • 2018 ACR/ARHP Annual Meeting
Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
Susan M. Goodman¹, Bo Shopsin², Allina A. Nocon¹, Andy O. Miller³, Michael W. Henry³, Sarah E. Grond¹, Elianna Kaplowitz¹, Thomas P. Sculco⁴, Linda A. Russell³, Laura T. Donlin⁵, Mark P. Figgie⁴ and Peter K. Sculco⁴, ¹Hospital for Special Surgery, New York, NY, ²Medicine and Microbiology, New York University School of Medicine, New York, NY, ³Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection than patients with osteoarthritis (OA). Disease modifying therapy is widely used…
Abstract Number: 2608 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
Iain B. McInnes¹, Alan J. Kivitz², Peter Nash³, Proton Rahman⁴, Juergen Rech⁵, Bruce Kirkham⁶, Sandra V. Navarra⁷, Kevin Ding⁸, Emma Ilsley⁹ and Luminita Pricop¹⁰, ¹University of Glasgow, Glasgow, United Kingdom, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Queensland, Brisbane, Australia, ⁴Memorial University, St John's, NF, Canada, ⁵University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, provided sustained improvement in the signs and symptoms of active psoriatic arthritis…
Abstract Number: 605 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Astrid Thiele⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However,…
Abstract Number: 1503 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima² and Naoki Ishiguro², ¹Nakatsugawa Municipal General Hospital, Nakatsugawa, Japan, ²Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Discontinuation of tumor necrosis factor inhibitor (TNFi) therapy in rheumatoid arthritis (RA) is attributable to various reasons. Above all, adverse event (AE) and insufficient…
Abstract Number: 2455 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
Judith Maro¹, Talia Menzin², Kenneth Hornbuckle³, Jon T. Giles⁴, Arthur Kavanaugh⁵, Thomas Dörner⁶, David Martin⁷, Jane Huang¹ and Claudia A. Salinas³, ¹Harvard Medical School, Boston, MA, ²Harvard Pilgrim Health Center, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Columbia University, New York, NY, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷Food and Drug Administration, Indianapolis, IN
Background/Purpose: Individuals with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), compared with…
Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Madeline J. Epsten¹, Lisa A. Mandl¹, Jackie Szymonifka² and Sergio Schwartzman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
Abstract Number: 610 • 2018 ACR/ARHP Annual Meeting
4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy
María Lourdes Ladehesa-Pineda¹, M. Carmen Castro-Villegas¹, Montserrat Romero Gómez¹, Clementina López-Medina², Laura Pérez Sánchez³, Ignacio Gómez-García⁴, Pilar Carreto Font⁵, Alejandro Escudero-Contreras², Eduardo Collantes-Estévez² and Pilar Font-Ugalde², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Rheumatology, Hospital Universitario Reina Sofia, CÓRDOBA, Spain, ⁵Centro de Salud Tudera de Duero. Área Este de Valladolid, Valladolid. SPAIN, Valladolid, Spain
Background/Purpose: Once sustained clinical remission is achieved under tratment with biological therapies, the most efficient strategy is optimization. Searching for the lowest effective dose for…
Abstract Number: 1597 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
Jürgen Braun¹, Bjoern Buehring¹, Xenofon Baraliakos¹, Lianne S. Gensler², Brian Porter³, Abhijit Shete⁴, Erhard Quebe-Fehling⁵ and Sibylle Haemmerle⁵, ¹Ruhr-University Bochum, Herne, Germany, ²University of California, San Francisco, CA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Low bone mass is common in ankylosing spondylitis (AS) and patients (pts) with AS have an increased risk of bone fracture.1-3 Treatment of AS…
Abstract Number: 2484 • 2018 ACR/ARHP Annual Meeting
Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Ayako Kubota¹, Toru Suguro¹, Arata Nakajima², Masato Sonobe³ and Kazuaki Tsuchiya¹, ¹Toho University Omori Medical Center, Tokyo, Japan, ²Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ³Toho University Sakura Medical Center, Chiba, Japan
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…
Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
Dongze Wu¹, Tingting Xu², Isaac T. Cheng¹, Steven H.M. Lam¹, Jiang Yue¹, Priscilla Wong¹, Edmund Li¹, Tena K. Li¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…
Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
Adeeba Al-Herz¹, Khulood Saleh², Adel Al-Awadhi³, Waleed Al-Kandari², Eman Hasan⁴, Aqeel Ghanem⁵, Yaser Ali⁵, Hebah Alhajeri⁶, Sawsan Hayat⁵, Ali Aldei⁷, Mohammad Hussain⁴, Ibrahim Nahar⁵, Fatemah Abutiban⁸, Ahmad Alenizi⁸, Khaled Mokaddem¹, Ahmad Khadrawy², Ammad Fazal², Agaz Zaman⁵, Ghada Mazloum⁵, Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁸ and Ahmed Al-Saber⁹, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Farwania Hospital, Farwania, Kuwait, ³Faculty of Medicine, Kuwait, Kuwait, ⁴Al-Amiri Hospital, Kuwait city, Kuwait, ⁵Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁶Division of Rheumatology, Mubarak Al-Kabeer Hospital, hawalli, Kuwait, ⁷Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait, ⁸Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁹Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…
Abstract Number: 1663 • 2018 ACR/ARHP Annual Meeting
Correlation between Biologics and Bath Ankylosing Spondylitis Metrology Index within the First 12 Months of Treatment in Patients with Axial Spondyloarthritis
Clare Longton¹, Marco Massarotti² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ²Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ³Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Several studies demonstrate efficacy of biologics on disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritides…

« Previous Page
1
…
5
6
7
8
9
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].